BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXFree Report) by 2.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,392,319 shares of the biotechnology company’s stock after buying an additional 302,270 shares during the quarter. Vanguard Group Inc. owned about 7.52% of BioCryst Pharmaceuticals worth $108,978,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Fifth Third Bancorp raised its position in shares of BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares during the last quarter. Fairfield Bush & CO. acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $34,000. State of Wyoming acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $35,000. Finally, Advisory Services Network LLC grew its holdings in shares of BioCryst Pharmaceuticals by 46.3% during the first quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,500 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, January 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.29.

View Our Latest Stock Analysis on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $4.73 on Thursday. The firm’s fifty day moving average is $5.38 and its two-hundred day moving average is $5.81. The firm has a market cap of $975.09 million, a price-to-earnings ratio of -4.01 and a beta of 1.90. BioCryst Pharmaceuticals, Inc. has a one year low of $4.59 and a one year high of $9.06.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Free Report) last issued its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $89.19 million. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.62 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

(Free Report)

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

See Also

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.